MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol
The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
BCL2 family members are subject to regulation at multiple levels, providing checks on their ability to contribute to tumorigenesis. However, findings on post-translational BCL2 phosphorylation in different systems have been difficult to integrate. Another antiapoptotic family member, MCL1, exhibits a difference in electrophoretic mobility upon phosphorylation induced by an activator of PKC (12-O-tetradecanoylphorbol 13-acetate; TPA) versus agents that act on microtubules or protein phosphatases 1/2A. A multiple pathway model is now presented, which demonstrates that MCL1 can undergo distinct phosphorylation events - mediated through separate signaling processes and involving different target sites - in cells that remain viable in the presence of TPA versus cells destined to die upon exposure to taxol or okadaic acid. Specifically, TPA induces phosphorylation at a conserved extracellular signal-regulated kinase (ERK) site in the PEST region (Thr 163) and slows turnover of the normally rapidly degraded MCL1 protein; however, okadaic acid and taxol induce ERK-independent MCL1 phosphorylation at additional discrete sites. These findings add a new dimension to our understanding of the complex regulation of antiapoptotic BCL2 family members by demonstrating that, in addition to transcriptional and post-transcriptional regulation, MCL1 is subject to multiple, separate, post-translational phosphorylation events, produced in living versus dying cells at ERK-inducible versus ERK-indepe…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MCL-1 phosphorylation at T163 decreased acutely upon trametinib treatment consistent with a loss of ERK phosphorylation59 and then rebounded at later time points coinciding with activation of JNK (Fig. S11A).”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [59]
In the citing paper
“ERK1/2 stabilise MCL1 through phosphorylation of T163 and indirectly through RSK-mediated inhibition of GSK39.”
From Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors (2019) · cites this paper as [9]
In the citing paper
“ERK-mediated phosphorylation of the MCL-1-PEST domain has been reported to limit MCL-1 degradation.”
From BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer (2022) · cites this paper as Domina et al., 2004
In the citing paper
“Our data therefore suggest that the induction of MCL-1 protein upon A-1155463 treatment could be mediated by FGFR4-driven ERK signaling (Domina et al., 2004) (Figure 5C).”
From BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer (2022) · cites this paper as Domina et al., 2004
Citations
Cites
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability
Sears, R., Nuckolls, F., Haura, E., Taya, Y., Tamai, K., & Nevins, J. R. (2000) · Genes & Development · doi:10.1101/gad.836800 · Cited by 1,393 · cited 2×
“Since the degradation of a variety of other PEST proteins is affected by phosphorylation (Rechsteiner, 1990; Clurman et al., 1996; Chen et al., 2000; Gregory and Hann, 2000; Sears et al., 2000; Koepp et al., 2001), we wondered whether this might likewise be the case with MCL1.”
BackgroundCurrent Protocols in Protein Science
(2018) · Current Protocols in Protein Science · doi:10.1002/(issn)1934-3663 · Cited by 1,189
Ca 2+ -Induced Apoptosis Through Calcineurin Dephosphorylation of BAD
Wang, H.-G., Pathan, N., Ethell, I. M., Krajewski, S., Yamaguchi, Y., Shibasaki, F., McKeon, F., Bobo, T., Franke, T. F., & Reed, J. C. (1999) · Science · doi:10.1126/science.284.5412.339 · Cited by 1,132 · cited 2×
“This latter modification has been extensively characterized in the case of the proapoptotic family member BAD (Scheid et al., 1999; Wang et al., 1999; Harada et al., 2001).”
BackgroundTsujimoto, Y., & Croce, C. M. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.14.5214 · Cited by 1,106 · cited 1×
“Expression of such viability-regulating gene products is often aberrant in cancer, as exemplified by the BCL2 overexpression seen in follicular lymphoma (Tsujimoto and Croce, 1986).”
BackgroundYamamoto, K., Ichijo, H., & Korsmeyer, S. J. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.12.8469 · Cited by 1,003 · cited 4×
“Conversion of Ser 70 and/or Ser 87 to Ala similarly resulted in enhanced viability promotion in human Jurkat or mouse WEHI231 cells (Yamamoto et al., 1999).”
BackgroundMethodInfluentialMCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2.
Kozopas, K. M., Yang, T., Buchan, H. L., Zhou, P., & Craig, R. W. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3516 · Cited by 961 · cited 3×
“…and slows turnover of the MCL1 protein We focused first on further studies with TPA, since we have extensively examined the effects of this agent on MCL1 expression and phosphorylation (Kozopas et al., 1993; Yang et al., 1996; Zhou et al., 1997; Townsend et al., 1998, 1999; Domina et al., 2000).”
BackgroundSelf-citationGeneration of Destabilized Green Fluorescent Protein as a Transcription Reporter
Li, X., Zhao, X., Fang, Y., Jiang, X., Duong, T., Fan, C., Huang, C.-C., & Kain, S. R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.52.34970 · Cited by 846 · cited 2×
“MCL1 turnover was assessed using standard methods (Li et al., 1998; Akgul et al., 2000; Gregory and Hann, 2000; Cuconati et al., 2003), by exposing cells to cycloheximide to inhibit protein synthesis (25 mg/ml) and monitoring loss of the existing MCL1 protein over time by Western blotting.”
MethodDevelopment and maintenance of B and T lymphocytes requires antiapoptotic MCL-1
Opferman, J. T., Letai, A., Beard, C., Sorcinelli, M. D., Ong, C. C., & Korsmeyer, S. J. (2003) · Nature · doi:10.1038/nature02067 · Cited by 801 · cited 1×
“A distinctive characteristic of MCL1 in these systems, as in differentiating cells like ML-1 cells, is its ability to act in a rapid but often shortterm fashion, under conditions of changing cell phenotype (Craig, 2002; Opferman et al., 2003).”
BackgroundPhosphorylation-Dependent Ubiquitination of Cyclin E by the SCF Fbw7 Ubiquitin Ligase
Koepp, D. M., Schaefer, L. K., Ye, X., Keyomarsi, K., Chu, C., Harper, J. W., & Elledge, S. J. (2001) · Science · doi:10.1126/science.1065203 · Cited by 762 · cited 1×
“Since the degradation of a variety of other PEST proteins is affected by phosphorylation (Rechsteiner, 1990; Clurman et al., 1996; Chen et al., 2000; Gregory and Hann, 2000; Sears et al., 2000; Koepp et al., 2001), we wondered whether this might likewise be the case with MCL1.”
BackgroundElimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation
Nijhawan, D., Fang, M., Traer, E., Zhong, Q., Gao, W., Du, F., & Wang, X. (2003) · Genes & Development · doi:10.1101/gad.1093903 · Cited by 591 · cited 1×
“Whatever the mechanism, the importance of MCL1 turnover in the control of cell viability has recently been brought to the fore by the demonstration that loss of MCL1 is an early step in apoptosis induced by DNA damage or by the viral E1A protein (Cuconati et al., 2003; Nijhawan et al., 2003).”
Background
Cited by
Items 201–300 of 342
Cunningham, D. L., Sarhan, A. R., Creese, A. J., Larkins, K. P. B., Zhao, H., Ferguson, H. R., Brookes, K., Marusiak, A. A., Cooper, H. J., & Heath, J. K. (2020) · Scientific Reports · doi:10.1038/s41598-020-64534-y · Cited by 19
Srinivasan, S., Leeman, S. E., & Amar, S. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00510-09 · Cited by 19
“Erk, similar to Akt, exerts an antiapoptotic effect and promotes cell survival (4, 7, 8, 20).”
BackgroundMitochondrial bioenergetics and networks in melanoma: an update
Giannitti, G., Paganoni, A. J. J., Marchesi, S., Garavaglia, R., & Fontana, F. (2025) · APOPTOSIS · doi:10.1007/s10495-025-02155-4 · Cited by 19
Protein Kinase Cβ Modulates Ligand-induced Cell Surface Death Receptor Accumulation
Meng, X. W., Heldebrant, M. P., Flatten, K. S., Loegering, D. A., Dai, H., Schneider, P. A., Gomez, T. S., Peterson, K. L., Trushin, S. A., Hess, A. D., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.057638 · Cited by 19
Kiss, E., Forika, G., Mohácsi, R., Németh, Z., Krenács, T., & Dank, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073598 · Cited by 18
Liang, Y., Niu, F., Xu, A., Jiang, L., Liu, C., Liang, H., Huang, Y., Shao, X., Mo, Z.-W., & Yuan, Y. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04551-z · Cited by 19
Josefsberg, L. B.-Y., Beider, K., Shimoni, A., Ostrovsky, O., Samookh, M., Peled, A., & Nagler, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033856 · Cited by 18
Wu, D., Li, M., Hong, Y., Li, J., Liu, Q., Sun, C., Li, L., Han, X., Deng, S., Feng, Y., et al. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.10.003 · Cited by 18
“ERK-mediated phosphorylation of Thr-163 might enhance MCL-1 protein stability [43], while Ser-159 phosphorylation of MCL-1 mediated by AKT or GSK3 could promote proteasomal degradation of MCL-1 [44].”
Olianas, M. C., Dedoni, S., & Onali, P. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13570 · Cited by 18
“Mcl-1 phosphorylation at Thr163 increases the protein stability against proteasomal degradation (Domina et al., 2004).”
BackgroundKozieł, K., Smigelskaite, J., Drasche, A., Enthammer, M., Ashraf, M., Khalid, S., & Troppmair, J. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2013.07.029 · Cited by 20
Sun, J., Ruan, F., Zeng, X., Xiang, J. Y., Li, X., Wu, P., Fung, K., & Liu, F. (2016) · APOPTOSIS · doi:10.1007/s10495-016-1273-y · Cited by 17
“sequences characteristic of short-lived protein, which makes it can rapidly response to environmental stimulus [42, 43].”
Perciavalle, R. M. (2012) · doi:10.21007/etd.cghs.2012.0242 · Cited by 18
“MCL-1 is a phosphorylated protein (Domina et al., 2004; Maurer et al., 2006; Morel et al., 2009); however, phosphatase-treatment of cell lysates did not abolish the 40 kD species”
BackgroundLAM-003, a new drug for treatment of tyrosine kinase inhibitor–resistant FLT3-ITD–positive AML
Beeharry, N., Landrette, S. F., Gayle, S., Hernandez, M., Grotzke, J. E., Young, P. R., Beckett, P., Zhang, X., Carter, B. Z., Andreeff, M., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019001068 · Cited by 16
Synergistic antitumor activity of regorafenib and rosuvastatin in colorectal cancer
Yuan, T., Wu, R., Wang, W., Liu, Y., Kong, W., Yang, B., He, Q., & Zhu, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1136114 · Cited by 17
“ERK1/ 2 phosphorylates MCL1 at Thr163 and increases its stability and anti-apoptotic activity (Domina et al., 2004).”
BackgroundVrana, J. A., Cleaveland, E. S., Eastman, A. R., & Craig, R. W. (2006) · APOPTOSIS · doi:10.1007/s10495-006-7787-y · Cited by 16
“However, ERK stabilized basal expression of the protein, probably reflecting the fact that ERK activation stimulates MCL1 phosphorylation at T163 in the PEST region and slows MCL1 protein turnover [31].”
BackgroundSelf-citationChong, S. J. F., Lai, J. X. H., Iskandar, K. B., Leong, B. J., Wang, C., Wang, Y., Guièze, R., Raman, D., Lim, R. H. F., Wu, C. J., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02694-4 · Cited by 17
“L Cell viability of acquired VEN-R OCI-AML2 cells following treatment with DPI (0.1 µM) for 2 h followed by VEN (0.2 µM) for 24 h. Cell viability was measured via MTT assay.”
InfluentialAhmed, T. A., Hayslip, J. W., & Leggas, M. L. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.09.002 · Cited by 15
Liu, Y., Xie, M., Song, T., Sheng, H., Yu, X., & Zhang, Z. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12325 · Cited by 15
“The Mcl-1 protein can be phosphorylated at multiple sites that distinctly regulate Mcl-1 protein turnover and interactions with pro-apoptotic proteins (Domina et al., 2004; Thomas et al., 2010).”
BackgroundThomas, L. W., Lam, C. W., Clark, R. E., White, M., Spiller, D. G., Moots, R. J., & Edwards, S. W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045088 · Cited by 14
“This region contains 2 large PEST domains, several potential phosphorylation sites [16,17], 2 caspase cleavage sites [18], and it”
BackgroundHornstein, T., Lehmann, S., Philipp, D., Detmer, S., Hoffmann, M. J., Peter, C., Wesselborg, S., Unfried, K., Windolf, J., Flohé, S., et al. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.3a1114-537rr · Cited by 15
“In this context it has been demonstrated that Erk might slow down Mcl-1 turnover by phosphorylation of the PEST region, again resulting in reduced protein degradation by the proteasome [42].”
BackgroundOverview of BH3 mimetics in ovarian cancer
Bufalo, D. D., & Damia, G. L. M. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102771 · Cited by 13
A novel Mcl1 variant inhibits apoptosis via increased Bim sequestration
Hagenbuchner, J., Kiechl‐Kohlendorfer, U., Obexer, P., & Ausserlechner, M. J. (2013) · Oncotarget · doi:10.18632/oncotarget.1147 · Cited by 13
“The second PEST sequence includes also two caspase cleavage sites (Asp127, Asp157) and several phosphorylation sites that are involved in regulating Mcl1 function and stability [3-6].”
BackgroundPerurena, N., Lock, R., Davis, R. A., Raghavan, S., Pilla, N. F., Ng, R. W. S., Loi, P., Guild, C. J., Miller, A. L., Sicińska, E., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101007 · Cited by 13
MCL1 as a Therapeutic Target in Parkinson's Disease?
Robinson, E. J., Aguiar, S. P., Smidt, M. P., & van der Heide, L. P. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.08.009 · Cited by 13
Zhang, Y., Xiao, Y., Dong, Q., Ouyang, W., & Qin, Q. (2019) · Journal of Food Science · doi:10.1111/1750-3841.14484 · Cited by 13
Leclerc, G. J., DeSalvo, J., Du, J., Gao, N., Leclerc, G. M., Lehrman, M. A., Lampidis, T. J., & Barredo, J. C. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.08.007 · Cited by 14
“Expression of the Mcl-1 protein has been shown to be important for BCR-ABL+ ALL cell survival [11–13], whereas reduced Mcl-1 levels allow the proapoptotic proteins (Noxa, Bim, Puma) to promote cell death via Bax and Bak [14].”
BackgroundHartman, M. L., Talar, B., Gajos-Michniewicz, A., & Czyż, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128796 · Cited by 15
“MCL-1 half-life can be prolonged, however, upon ERK-1/2-dependent phosphorylation of MCL-1 at Thr(163) [66,67], and this effect has been also reported in melanoma cells [68].”
BackgroundSun, J., Xiang, J., Zeng, X., Li, X., Wu, P., Fung, K., & Liu, F. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.09.024 · Cited by 12
LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers
Li, C., Syed, M. U., Nimbalkar, A., Shen, Y., Vieira, M. D., Fraser, C., Inde, Z., Qin, X., Ouyang, J., Kreuzer, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58753-y · Cited by 11
“MCL-1 phosphorylation at T163 decreased acutely upon trametinib treatment consistent with a loss of ERK phosphorylation 59 and then rebounded at later time points coinciding with activation of JNK (Fig.”
WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer
Yamamoto, G., Tanaka, K., Kamata, R., Saito, H., Yamamori-Morita, T., Nakao, T., Liu, J., Mori, S., Yagishita, S., Hamada, A., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2024.217414 · Cited by 11
Signaling of endothelial cytoprotection in transplantation
Charreau, B. L. (2012) · Human Immunology · doi:10.1016/j.humimm.2012.07.012 · Cited by 11
Li, X., He, J., Li, B., Gao, M., Zeng, Y., Lian, J., Shi, C., Huang, Y., & He, F. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22837 · Cited by 11
“For examples, phosphorylation of Mcl-1 on Thr163 site in its PEST region by ERK or JNK protects Mcl-1 from degradation and increases its protein level.(29,30) FIGURE 3 Rosiglitazone alleviates the (−)-G-induced Mcl-1 via inhibiting the (−)-G-triggered JNK phosphorylation.”
BackgroundZinc Sensitizes Lung Cancer Cells to Anoikis through Down-Regulation of Akt and Caveolin-1
Pramchu-em, C., Meksawan, K., & Pithi Chanvorachote, B. (2016) · Nutrition and Cancer · doi:10.1080/01635581.2016.1142582 · Cited by 11
“phosphorylation of ERK induced by TPA at Thr92 and Thr163 increased the stability of Mcl-1 in breast cancer cells and BL41-3 Burkitt lymphoma cells (38,39).”
BackgroundKojima, S., Hyakutake, A., Koshikawa, N., Nakagawara, A., & Takenaga, K. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.11.086 · Cited by 10
Wiggins, C. M., Johnson, M. A., & Cook, S. J. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.01.004 · Cited by 13
The Intrinsic Pathway of Apoptosis
Kaufmann, S. H. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-221-2_1 · Cited by 15
Brüning, A., Burger, P., Vogel, M., Gingelmaier, A., Friese, K., & Burges, A. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9281-1 · Cited by 10
“In contrast, phosphorylation of mcl-1 at threonin-163 by activation of the RAS/RAF/ERK pathway has been described to induce stabilization of the mcl-1 protein [18, 19].”
Chu, R., Alford, S. E., Hart, K., Kothari, A., Mackintosh, S. G., Kovak, M. R., & Chambers, T. C. (2016) · Oncotarget · doi:10.18632/oncotarget.12586 · Cited by 9
“Other studies have indicated that certain phosphorylation sites, including T92 and T163 which are among the sites mutated in Mcl-1-9A, regulate Mcl1 stability and prolong its half-life [7, 8].”
BackgroundSteelman, L. S., Abrams, S. L., Ruvolo, P. P., Ruvolo, V. R., Cocco, L., Ratti, S., Martelli, A. M., Neri, L. M., Candido, S., Libra, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22956 · Cited by 8
Mahfoudhi, E., Ricordel, C., Lécuyer, G., Mouric, C., Léna, H., & Pedeux, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.853501 · Cited by 9
Hardt, R., Dehghani, A., Schoor, C., Gödderz, M. P. O., Winter, N. C., Ahmadi, S., Sharma, R. K., Schork, K., Eisenacher, M., Gieselmann, V., et al. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04892-8 · Cited by 8
“This region, which is frequently also referred to as PEST domain (proline (P)/glutamic acid (E)/serine (S)/threonine(T)-rich domain), was shown previously to facilitate proteolytic cleavage (and degradation) of proteins [99, 100], and its phosphorylation has been shown to regulate proteolytic degradation [101], furthe…”
BackgroundModi, P., Balakrishnan, K., Yang, Q., Wierda, W. G., Keating, M. J., & Gandhi, V. V. (2017) · Oncotarget · doi:10.18632/oncotarget.15180 · Cited by 8
Suzuki, R., Kitamura, Y., Nakamura, Y., Akashi, H., Ogawa, Y., Kawada, H., & Ando, K. (2020) · Oncotarget · doi:10.18632/oncotarget.27775 · Cited by 8
“As one of the mechanisms by which RAS mutations induce drug resistance, deregulated RAS-RAF-MEK-ERK activity contributes to anti-apoptotic molecules in MM cells, and is associated with greater relapse, shorter survival, and drug resistance [6, 39].”
Combining chemo-, hormonal and targeted therapies to treat breast cancer (Review)
McCubrey, J. A., Bonati, A., Libra, M., Stivala, F., Martelli, A. M., Franklin, R. A., Navolanic, P. M., & Steelman, L. S. (2008) · Molecular Medicine Reports · doi:10.3892/mmr.1.2.139 · Cited by 11
“Certain chemotherapeutic drugs, such as taxol, will induce Mcl-1 phosphorylation at sites other than those phosphorylated by ERK (T163) (88).”
BackgroundInfluentialMCL1 modulates mTORC1 signaling to promote bioenergetics and tumorigenesis
Gui, W., Páral, P., Dhamija, B., Hagag, E., Dusa, M., Humajová, J., Francová, P., Kučka, J., Pankrác, J., Schütz, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66831-4 · Cited by 9
Liu, T., Yue, X., Chen, X., Yan, R., Wu, C., Li, Y., Bu, X., Han, H., & Liu, R. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00927-9 · Cited by 7
“Conversely, the level of MCL-1 phosphorylation at Thr163 was markedly decreased in cells with sunitinib plus nilotinib treatment, whose phosphorylation indicating the reduction of ubiquitination and enhancement of stability [26].”
Chemical dissection of selective myeloid leukemia-1 inhibitors: How they were found and evolved
Wang, L., Chen, Y., Zhang, M., Liu, J., Li, H., Li, W., Wu, S., Zhang, Y., Li, W., & Wang, B. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117168 · Cited by 8
Lee, H., Nam, J., Shin, J., Hong, I., Yang, I., You, M., & Cho, S. (2015) · Head & Neck · doi:10.1002/hed.24096 · Cited by 7
Yao, L., Zhao, Q., Ding, Y., Lei, Z., Hao, Y., Chen, J., Xue, Q., Li, X., Huang, Q., Tang, D., et al. (2022) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0598 · Cited by 7
“In particular, glycogen synthase kinase 3 beta (GSK-3 β ) phosphorylates MCL-1 and facilitates its degradation 33 , whereas ERK1/2 phosphorylates MCL-1 and increases its protein stabilization 34 .”
Clybouw, C., Mchichi, B. E., Hadji, A., Portier, A., Auffredou, M., Arnoult, D., Leca, G., & Vázquez, A. (2008) · Oncogene · doi:10.1038/sj.onc.1211009 · Cited by 8
“Mcl-1 can be modified through various means including phosphorylation (Domina et al., 2004; Maurer et al., 2006; Kobayashi et al., 2007) and degradation by the proteasome (Cuconati et al.”
BackgroundJamil, S., Wang, S. W., Bondy, L., Mojtabavi, S., & Duronio, V. (2010) · Biochemistry and Cell Biology · doi:10.1139/o10-004 · Cited by 7
Aka, Y., Karakaş, B., Acikbas, U., Başağa, H., Gül, Ö., & Kütük, Ö. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2021.106028 · Cited by 6
Hartman, M. L., Koziej, P., Kluszczyńska, K., & Czyż, M. (2023) · Cancers · doi:10.3390/cancers15194799 · Cited by 6
“Several complex relationships between these proteins that have been shown previously [50,51,65–68] are reflected in our study.”
Sahoo, S., Suvarna, S., Chandra, A., Wahi, S., Kumar, P., & Khanna, G. (2013) · PubMed · Cited by 9
Waldron, N. R., Silva, D. D., Westaby, D., Jiménez‐Vacas, J. M., Taylor, J., & Sharp, A. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03441-x · Cited by 5
Vaculová, A. H., Hofmanová, J., Procházková, J., & Kozubík, A. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.09.019 · Cited by 6
Sarkar, M., Martufi, M., Román-Trufero, M., Wang, Y.-F., Whilding, C., Dormann, D., Sabbattini, P. M. R., & Dillon, N. (2021) · Molecular Biology of the Cell · doi:10.1091/mbc.e21-02-0089 · Cited by 6
“ERK also phosphorylates and stabilizes the Bcl2 family member Mcl-1, enhancing its antiapoptotic activity (Domina et al. , 2004).”
Moriizumi, H., Kubota, Y., Tsuchiya, T., Naka, R., & Takekawa, M. (2023) · FEBS Open Bio · doi:10.1002/2211-5463.13574 · Cited by 6
Lv, X., Tan, G., Yao, Y., Lv, L., Deng, X., Dong, L., Li, S., Li, L., & Xu, Y. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3493 · Cited by 5
Hsueh, S.-P., Du, J.-L., Hsu, W.-B., Fang, C.-A., Liu, H., & Wang, W.-B. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.04.019 · Cited by 5
“Secondary, previous studies have shown that activation of ERK pathway causes many protective effects against chemotherapeutic agents, such as up-regulation of antiapoptotic proteins Bcl-2 and Bcl-XL [46,47], phosphorylation and inactivation of pro-apoptotic proteins Bad and Bim [48–50], and phosphorylation and stabili…”
BackgroundLow-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models
Tesei, A., Leonetti, C., Zupi, G., Scarsella, M., Brigliadori, G., Ulivi, P., Fabbri, F., Arienti, C., Amadori, D., Passardi, A., et al. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00993.x · Cited by 5
“Notably, the anti-apoptotic Bcl-2 family member mcl-1, which appears to depend on ERK-mediated phosphorylation [55–58], is believed to be involved in resistance to anticancer drugs and to recurrence in gastric cancer [59, 60].”
BackgroundLv, J.-J., Liu, Y.-J., Mo, Y.-H., Deng, L.-Y., Liu, Y., Li, H., Zhang, L., & Yang, W. (2025) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2025.138006 · Cited by 4
Ma, G., Wang, D., Deng, Y., Huang, W., Zhai, Y., & Sun, S. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217962 · Cited by 4
Palachai, N., Buranrat, B., Pariwatthanakun, C., Noisa, P., & Mairuae, N. (2025) · Scientific Reports · doi:10.1038/s41598-025-28739-3 · Cited by 4
“Mcl-1, an anti-apoptotic member of the Bcl-2 family, is phosphorylated by ERK1/2, thus increasing its stability and enhancing its anti-apoptotic activity 42 .”
Lee, Y. S., Good, J., Awais, N., Eschle, B. K., Lineberry, M. S., Lin, J., Wunderlich, M., Thibodeau, J., Edwards, H. J., Teo, J. L., et al. (2026) · Blood Neoplasia · doi:10.1016/j.bneo.2026.100202 · Cited by 4
“41 Both MCL-1 and eIF4A initially decreased but rebounded or increased after 24 hours, highlighting a dynamic response to zota-tifin.”
Li, B., Zhou, M., Wang, J., Xu, H., & Yang, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.663944 · Cited by 4
“The mRNA level of Mcl-1 is verified to be promoted in response to ERK1/2 pathway via CREB or transcription factor ELK1 (40).”
BackgroundLi, M.-Y., Liu, L., Xin, Q., Zhou, J., Zhang, X., Zhang, R., Wu, Z., Yi, J., & Dong, M. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2023.159332 · Cited by 7
Tannic Acid and Ethyl Gallate Potentialize Paclitaxel Effect on Microtubule Dynamics in Hep3B Cells
Sánchez‐Carranza, J. N., Redondo‐Horcajo, M., Barasoaín, I., Escobar-Aguilar, E. A., Millán‐Pacheco, C., Álvarez, L., Vidal, E. S., Díaz, J. F., & González‐Maya, L. (2023) · Pharmaceuticals · doi:10.3390/ph16111579 · Cited by 5
“…it has been widely studied that ERK1/2 promotes cell survival by enhancing the effect of anti-apoptotic molecules, for example, Mcl-1, a member of the BCL2 family, which is phosphorylated at threonine 163 by ERK1/2, thereby increasing its stability and enhancing its anti-apoptotic activity [39].”
BackgroundApoptosis, senescence and cancer (cancer drug discovery and development)
Young, A. R. J. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604944 · Cited by 4
Hong, J., Zheng, W., & Cai, X. (2022) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207325666220830145026 · Cited by 3
Korsensky, L., Chorev, D. S., Saleem, H., Heller, R., Rabinovitz, S., Haif, S., Dahan, N., Ziv, T., & Ron, D. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110085 · Cited by 3
Sim, K. M., Kim, S. Y., Hwang, S., Park, S., Lee, B. R., Nam, K., Oh, S., & Kim, I. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110554 · Cited by 3
Roles of Apoptosis-Regulating Bcl-2 Family Genes in AML
Reed, J. C. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1393-0_3 · Cited by 4
McCubrey, J. A., Franklin, R. A., Bertrand, F. E., Taylor, J. R., Chappell, W. H., Midgett, M. L., Wong, E. W. T., Abrams, S. L., Stadelman, K. M., Misaghian, N., et al. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-474-2_7 · Cited by 3
“The Raf/ MEK/ERK pathway can also modulate the activity of many proteins involved in apoptosis, including Bcl-2, Bad, Bim, Mcl-1, caspase 9, and survivin [36–45].”
BackgroundInhibition of MEK sensitizes gastric cancer cells to TRAIL-induced apoptosis
Wu, P., Cheng, Y., WANG, J. Y., Zhang, X. D., & ZHANG, L. J. (2013) · Neoplasma · doi:10.4149/neo_2014_019 · Cited by 3
“[37] DOMINA AM, VRANA JA, GREGORY MA, HANN SR,”
BackgroundJoseph, D., Kongoli, F., You, F., & Inufusa, H. (2026) · Cell Death Discovery · doi:10.1038/s41420-026-03066-2 · Cited by 2
Substituted indole Mcl-1 inhibitors: a patent evaluation (WO2015148854A1)
Song, T., Wang, Z., & Zhang, Z. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2016.1240786 · Cited by 2
Bao, G., Zhou, L., Wang, T.-J., He, L., & Liu, T. (2014) · Bulletin of the Korean Chemical Society · doi:10.5012/bkcs.2014.35.7.2097 · Cited by 1
Wijaya, D. A., Louisa, M., Wibowo, H., Taslim, A., Permata, T. B. M., Handoko, H., Nuryadi, E., Kodrat, H., & Gondhowiardjo, S. A. (2021) · Journal of Herbmed Pharmacology · doi:10.34172/jhp.2021.18 · Cited by 1
ERKed by too much signaling: from oncogenic driver to therapeutic vulnerability
Farnsworth, D., Naznin, F., Subramaniam, A., Sew, K., & Lockwood, W. W. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06084-6 · Cited by 1
“ERK suppresses the pro-apoptotic factor BIM through transcriptional regulation and by stimulating its proteasomal degradation [59, 60], and can also promote expression and stability of anti-apoptotic factors [61, 62].”
Mesa, R. A., & Kaufmann, S. H. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-322-6_6 · Cited by 1
Role of Sphingolipids in Hematological Malignancies: Myeloproliferative Disorders
Moorthi, S., & Luberto, C. (2015) · Springer eBooks · doi:10.1007/978-3-319-20750-6_3 · Cited by 1
Is M cl‐1 L the new anti‐apoptotic effector of B ‐ RAFV 600E in melanoma?
Bergamaschi, D. (2014) · Experimental Dermatology · doi:10.1111/exd.12312 · Cited by 1
The regulation of GSK‐3β in nervous system
Tan, D., Chen, K., & Zhu, Z. (2017) · Ibrain · doi:10.1002/j.2769-2795.2017.tb00018.x · Cited by 1
Molecular-Targeted Therapy for Melanoma
RUSSO, A. E., Bevelacqua, Y., Marconi, A., Veronesi, A., & Libra, M. (2011) · Springer eBooks · doi:10.1007/978-1-60761-433-3_20 · Cited by 1
Novel Therapeutic Strategies for Pancreatic Cancer
Quinn, B. A. (2014) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/t39h-kj31 · Cited by 2
“Thr(163) can be phosphorylated by ERK leading to the increased half-life of the protein (33).”
BackgroundJin, Y., Ding, K., Li, H., Xue, M., Shi, X., Wang, C., & Pan, J. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01407-6 · Cited by 1
Konopleva, M. Y., Milella, M., Ruvolo, P. P., Watts, J. C., Ricciardi, M. R., Korchin, B., Teresa, M., Bornmann, W. G., Tsao, T., Bergamo, P., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02339-y · Cited by 1
Modi, P. (2015) · Digital Commons-TMC (Texas Medical Center)
Pathophysiology of Protein Kinase C Isozymes in Chronic Lymphocytic Leukaemia
Cawley, J. C., & Joseph, R. E. (2012) · InTech eBooks · doi:10.5772/28964
Eipper-Mains, M. A. (2004) · DSpace@MIT (Massachusetts Institute of Technology)
TRAIL resistance through transcriptional control of MCL-1
Son, J. K. (2009) · Texas ScholarWorks (Texas Digital Library)
Modulation of ros-induced apoptosis of HL-60 cells by thioredoxin and phosphatase inhibitors
Yang, M. (2005) · Texas ScholarWorks (Texas Digital Library)
Bcl-xL/xS phosphorylation regulates the sensitivity of PC12 cells to apoptosis
Qi, J. (2009) · University Library - University of Saskatchewan (University of Saskatchewan)
Schüll, S. (2014) · Kölner Universitäts PublikationsServer (Universität zu Köln)
MOLECULAR ADAPTATION TO ANTI-CANCER CHEMOTHERAPY IN LEUKEMIA
Zimmerman, E. I. (2011) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/1b1k-v207
The Role of BCL-2 Family in Clinical Response of Chronic Lymphocytic Leukemia
Al-harbi, S. (2012) · OhioLink ETD Center (Ohio Library and Information Network)
Peall, A. (2017) · Figshare
Omari, S. (2014) · TSpace (University of Toronto)
Alase, A. A. (2015) · Bradford Scholars (University of Bradford)
Metadata
- Authors
- Domina, A. M., Vrana, J. A., Gregory, M. A., Hann, S. R., & Craig, R. W.
- Affiliations
- Dartmouth College (US)
- Vanderbilt University (US)
- Corresponding author
- Craig, Ruth W
- Venue
- Oncogene
- Published
- 2004-06-07
- Volume
- 23
- Issue
- 31
- Pages
- 5301-5315
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2041230280
- Cited by
- 327
- References
- 58
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 6 · 2023: 15 · 2022: 13 · 2021: 24 · 2020: 10 · 2019: 16 · 2018: 9 · 2017: 15 · 2016: 14 · 2015: 16 · 2014: 29 · 2013: 26 · 2012: 25
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Hitchcock Foundation
- National Cancer Institute (R01-CA57359, R01CA057359)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- Mcl-1, protein phosphorylation, ERK signaling, protein stabilization, Bcl-2 family proteins, anti-apoptotic proteins, okadaic acid, paclitaxel, microtubule stabilization, protein phosphatase 2A, phorbol myristate acetate, post-translational regulation, apoptosis
- MeSH terms
- Amino Acid Sequence, Animals, Antineoplastic Agents, Phytogenic, Binding Sites, Carcinogens, Cell Survival, Dogs, Dose-Response Relationship, Drug, Enzyme Activation, Enzyme Inhibitors, Cricetinae, Humans, Molecular Sequence Data, Neoplasm Proteins, Peptide Mapping, Phosphorylation, Precipitin Tests, Protein Kinase C, Tetradecanoylphorbol Acetate, Threonine, Time Factors, Transfection, Signal Transduction, CHO Cells, Apoptosis, Paclitaxel, Protein Structure, Tertiary, Proto-Oncogene Proteins c-bcl-2, Okadaic Acid, Mitogen-Activated Protein Kinases, MAP Kinase Signaling System, Cell Line, Tumor, Mice, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.